Webster K. Cavenee, PhD
Director, Ludwig Institute for Cancer Research; Distinguished Professor, University of California, San Diego, California
Recognized for having provided the first indisputable evidence of tumor suppressor genes, Dr. Cavenee has conducted research that has fundamentally changed the understanding of tumor initiation and progression.
Dr. Cavenee’s recent research has focused on gliomas, and his team has found that an abnormal version of EGFR, named EGFRviii, is common in the most rapidly progressive primary brain tumors in humans. His team has been working to develop an understanding of resistance to targeted therapies, hypothesizing that targeting these genes, together with the primary target, will lead to more durable responses.
2012 Elected to the Leopoldina German Academy of Science2008 Elected Fellow, American Association for the Advancement of Science2007 Elected to the Institute of Medicine2007 AACR-Princess Takamatsu Award2007 Albert Szent-Gyorgyi Prize, National Foundation for Cancer Research2003 Fellow, National Foundation for Cancer Research1998-1999 President, AACR1997 Fellow, American Academy of Microbiology1997 Elected Member, National Academy of Sciences, Washington, DC1994 Farber Prize, American Association of Neurological Surgeons1994 Fellow, International Union Against Cancer1994-1997 Board of Directors, AACR1990 Charles S. Mott Award, General Motors Cancer Research Foundation1988 Award for Outstanding Achievement in Cancer Research (Rhoads Prize), AACR1977 PhD, University of Kansas School of Medicine